August 05, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE	**:**	**BAYERCROP**
SCRIP CODE	**:**	**506285**

Dear Sir / Madam,

Sub.: Outcome of Board Meeting – August 05, 2026.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., August 05, 2026, has inter alia, approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026. We attach a copy of the same along with the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

Further, please take a note that the Board Meeting commenced at 04:30 p.m. (IST) and concluded at 05:00 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Ratan Shetty
Digitally signed by Bharati Ratan Shetty
Date: 2026.08.05 18:03:46 +05'30'

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No.: ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center
Tower 3, 31st floor,
Senapati Bapat Marg,
Elphinstone Road (West)
Mumbai-400013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of BAYER CROPSCIENCE LIMITED ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations).

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

MOHAMMED SAIFUDDIN BENGALI
Digitally signed by MOHAMMED SAIFUDDIN BENGALI
Date: 2026.08.05 17:49:34 +05'30'

Mohammed Bengali
(Partner)
Membership No. 105828
UDIN: 26105828GBPQEK2756

Mumbai
August 05, 2026

BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

PART I — ₹ in Millions

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

PARTICULARS	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from Operations	18,350	11,008	19,146	56,750
Other Income (Note 4)	889	466	187	950
Total Income	**19,239**	**11,474**	**19,333**	**57,700**
Expenses				
Cost of Materials Consumed	10,427	8,927	10,395	31,525
Purchases of Stock-in-Trade	683	319	630	2,200
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(743)	(3,677)	680	50
Employee Benefits Expense	1,128	1,060	1,043	4,381
Finance Costs	43	55	47	198
Depreciation and Amortisation Expense	501	376	272	940
Other Expenses	3,179	2,350	2,914	9,857
Total Expenses	**15,218**	**9,410**	**15,981**	**49,151**
Profit Before Tax	**4,021**	**2,064**	**3,352**	**8,549**
Tax Expense/ (Credit)				
- Current Tax	814	429	580	1,643
- Deferred Tax	(9)	14	(15)	14
Total Tax Expense	805	443	565	1,657
Profit for the period/ year	**3,216**	**1,621**	**2,787**	**6,892**
Other Comprehensive Income				
Items that will not be reclassified to profit or loss:				
- Remeasurement loss of Defined Benefit Plan	(7)	(110)	(6)	(162)
- Tax on remeasurement of Defined Benefit Plan	2	28	2	41
Total Other Comprehensive (Loss)/ Income	**(5)**	**(82)**	**(4)**	**(121)**
Total Comprehensive Income for the period/ year	**3,211**	**1,539**	**2,783**	**6,771**
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449
Reserves (excluding Revaluation Reserve as per Balance Sheet)				29,208
Earnings per share (basic and diluted) (^ not annualised) (in ₹)	71.56^	36.07^	62.01^	153.35

NOTES:

1. The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.

2. The Company does not have any subsidiary, joint venture, or associate company and consequently, the Company is not required to prepare consolidated financial results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025.

3. The figures for the quarter ended March 31, 2026, are the balancing figures between audited figures for the financial year ended March 31, 2026 and the unaudited published year to date figures upto the third quarter of the previous financial year, which were subjected to limited review.

4. Other Income includes:

₹ in Millions

PARTICULARS	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
Gain on Divestment of Marketing Rights for Formulated Products	639	223	-	223

5. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 5, 2026. The above results have been subjected to limited review by the Statutory Auditors of the Company.

By Order of the Board

VINIT RAJESH JINDAL

Digitally signed by VINIT RAJESH JINDAL
Date: 2026.08.05 17:21:28 +05'30'

Vinit Jindal
Executive Director and Chief Financial Officer
DIN: 10849465

Place: Thane
Date: August 5, 2026

DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS